NGM Biopharmaceuticals, a Phase 2 biotech developing therapies for NASH and type 2 diabetes, raised $107 million by offering 6.7 million shares at $16, the high end of the range of $14 to $16. NGM Biopharmaceuticals plans to list on the Nasdaq under the symbol NGM. Goldman Sachs, Citi and Cowen acted as lead managers on the deal.
